Pfizer Inc. and BioNTech SE announced on August 27 that the U.S. Food and Drug Administration has approved a supplemental Biologics License Application for their updated 2026–2027 COVID-19 vaccine formula, called COMIRNATY XFG, according to the companies’ announcement reported by Yahoo Finance.
The updated formula targets the XFG variant of the virus and is authorized for adults aged 65 and older, as well as individuals aged 5 to 64 who have high-risk underlying conditions, per the report. The approval is based on clinical, real-world, and manufacturing data that the companies say demonstrate strong immune responses against currently circulating strains, and it aligns with FDA strain guidance issued for fall 2026.
According to the report, the clearance helps secure Pfizer and BioNTech’s position in seasonal COVID-19 immunizations by realigning COMIRNATY with current viral strains. This is described as protecting a recurring revenue stream and stabilizing cash flow for both companies as they navigate broader shifts in their product portfolios.
For Pfizer, the report states that predictable seasonal vaccine demand supports margins and cash flow while the company works to optimize manufacturing and fund pipeline programs outside of COVID-19, including in oncology, obesity, and immunology. The steady vaccine revenue is also described as a cushion against upcoming losses of patent exclusivity on other products.
For BioNTech, the report frames the approval as validation of its mRNA vaccine platform and commercial execution, helping preserve what is described as a strong balance sheet with minimal debt and substantial cash reserves. This financial position is said to allow BioNTech to fund operational expenses and advance late-stage oncology trials without needing to raise dilutive financing.
The report also outlines risks facing both companies. It notes that demand for COVID-19 boosters has
Key facts
- FDA approved a supplemental Biologics License Application for Pfizer and BioNTech’s updated 2026–2027 COVID-19 vaccine, COMIRNATY XFG, announced August 27
- The formula targets the XFG variant and is authorized for adults 65+ and people aged 5–64 with high-risk conditions
- Approval is based on clinical, real-world, and manufacturing data and aligns with FDA strain guidance for fall 2026
- The report says COVID-19 booster demand has normalized compared to pandemic peaks, creating long-term market contraction risk
- Pfizer faces risk from a volatile COVID revenue base amid elevated debt; BioNTech faces risk from heavy operating losses relative to vaccine revenue